Acorda Therapeutics 3Q Loss Widens On Costs
Acorda Therapeutics' 3rd-quarter loss widens slightly as costs more than offset drug sales
12:10PM 11/03/09
FDA Delays Ruling On Acorda's MS Drug Until Jan.
Acorda Therapeutics says FDA extends Fampridine-SR review by 3 months until Jan. 22
06:38AM 10/22/09
Galleon's Biotech Stock Holdings: BioBuzz
If the troubled hedge fund liquidates, it will sell biotech stocks.
01:53PM 10/20/09
Busy Biotech-Drug Calendar for Next Week: BioBuzz
Earnings and FDA approval decisions on tap for investors.
12:18PM 10/16/09
Citigroup, Nokia, Capital 1, Safeway Big Movers
Citigroup, Nokia, Capital 1, Safeway, McClatchy are among big market movers Thursday
05:51PM 10/15/09
Premarket Roundup: Insurers, Acorda Therapeutics
Premarket roundup: Insurers downgraded on pricing worries, Acorda Therapeutics shares leap
09:37AM 10/15/09
Ahead Of The Bell: Acorda Surges On MS Drug Review
Acorda climbs as FDA panel recommends approval for multiple sclerosis drug Fampridine-SR
08:31AM 10/15/09
FDA Decision Next Up for Acorda: BioBuzz
Panel experts put aside skeptical FDA review to recommend drug's approval.
07:11AM 10/15/09
FDA Panel Backs Acorda Therapeutics Treatment
FDA panel favors approval for Acorda Therapeutics' multiple sclerosis drug
05:08PM 10/14/09
FDA Panel Votes 'Yes' on Acorda Drug Efficacy: BioBuzz
FDA advisory panel reviewing Acorda's multiple sclerosis drug.
03:20PM 10/14/09
Supervalu, NetApp, Scientific Learning Big Movers
Supervalu, NetApp, Scientific Learning, Infosys, Acorda are among big market movers Friday
05:47PM 10/09/09
Hemispherx CEO Carter Speaks: BioBuzz
CEO says little new on status of the FDA's Ampligen review.
12:11PM 10/09/09
Acorda's MS Drug Faces Skeptical FDA
Acorda Therapeutics faces skeptical FDA in review for multiple sclerosis drug Fampridine-SR
10:22AM 10/09/09
FDA Questions Efficacy of Acorda's MS Drug: BioBuzz
Agency asks if Amaya's walking benefit is clinically meaningful.
09:11AM 10/09/09



Connect with TheStreet